MA-ALLURION-TECHNOLOGIES
26.1.2021 13:02:12 CET | Business Wire | Press release
Allurion® Technologies , a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced a major milestone for its AllurionTM Weight Loss Program with the launch of its new digital health offering featuring the Allurion TM Health Tracker smartwatch, Allurion® Connected Scale, Allurion® mobile app, and the Allurion TM Clinic Dashboard, the first in a series of new provider services that make up the Allurion TM Virtual Care Suite.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005074/en/
The Allurion Connected Scale and Health Tracker measure all aspects of body composition including weight, body fat, muscle mass, as well as activity data such as steps, exercise, and sleep. These measurements effortlessly sync with the Allurion mobile app, which charts and analyzes the data, provides real-time insights to the user, and enables sharing with their provider and care team.
The Allurion Clinic Dashboard helps providers understand their aggregate patient results and access real-time insights to tailor care, ultimately leading to improved outcomes. The Allurion Clinic Dashboard is a turnkey solution that enables providers to track a variety of clinic-level metrics such as weight loss and patient engagement over time, benchmarking their performance with other clinics across the globe.
Additional capabilities of the Allurion Virtual Care Suite will be released throughout 2021, making it simple for providers to monitor, communicate and deliver care via a suite of tools which include telehealth and AI-powered weight-loss guidance. This suite, available to all providers who offer the Allurion Program, enables seamless ongoing support and leads to markedly improved patient satisfaction.
“The Allurion Virtual Care Suite is designed to work hand-in-hand with the Elipse® Balloon and our nutritional and behavior change program to deliver life-changing results to consumers and real-time data and insights to our providers,” said Shantanu Gaur, M.D., Allurion’s co-founder and Chief Executive Officer. “Our digital health offering creates an ecosystem for consumers and providers that will not only improve short-term outcomes but also facilitate weight management over a lifetime.”
As a further demonstration of Allurion’s commitment to consumer satisfaction and best-in-class results, the company is also announcing today the launch of the Allurion Assurance Plus Warranty program. Allurion patients around the world will now automatically be enrolled in the new Allurion Warranty program at no charge. The Allurion Assurance Plus Warranty program provides patients piece of mind that qualifying rare events related to the Elipse® Balloon will be eligible for coverage and out-of-pocket financial assistance.
“Allurion is committed to provide patients a best-in-class experience, and their safety is our top priority,” said Ram Chuttani, M.D., Allurion’s Chief Medical Officer “We are delighted to launch the Allurion Assurance Plus Warranty to give our patients added comfort and confidence as they proceed through their weight loss journey.”
About Allurion Technologies
Allurion Technologies is dedicated to helping people realize a healthy life with innovative, scalable and trusted weight loss experiences. The company's flagship product, the Allurion Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss, the Allurion Honeymoon from Hunger nutritional and behavior change program, and the Allurion Virtual Care Suite including the Allurion Connected Scale, Allurion Health Tracker smartwatch, Allurion mobile app, Allurion Clinic Dashboard and Allurion Insights Portal. Learn more about Allurion online at www.allurion.com . Allurion and Elipse are trademarks of Allurion Technologies, Inc. in the United States and countries around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology from TII, Extending Confidential AI Across the Full Lifecycle with Post-Quantum Protection4.5.2026 10:23:00 CEST | Press release
New capabilities make it possible to safely deploy AI agents on the most sensitive and regulated data — with hardware-enforced, verifiable rules and cryptographic guarantees built to withstand quantum computing OPAQUE, the Confidential AI company headquartered in San Francisco, California, today announced it has acquired advanced cryptographic AI technologies from the Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi's Advanced Technology Research Council (ATRC). The acquired technology — already proven in real-world use cases — adds two critical capabilities to OPAQUE's platform: confidential AI model training powered by advanced cryptographic techniques such as multi-party computation and fully homomorphic encryption, as well as post-quantum cryptographic protections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504705475/en/ OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology
Forbes Includes Philip Morris International in Its Net Zero Leaders List4.5.2026 10:00:00 CEST | Press release
PMI ranks number 4, marking its fourth consecutive year of recognition for making significant strides toward reaching net zero carbon footprint goals Philip Morris International (PMI) (NYSE: PM) has been included once more in Forbes’ 2026 Net Zero Leaders1 list, recognizing its leadership and continued progress in advancing climate action across its global operations. The Forbes Net Zero Leaders list highlights U.S. publicly listed companies best positioned to achieve net zero emissions by 2050, based on measurable performance rather than commitments alone. Despite most companies aligning to a 2050 net zero horizon, PMI remains committed to reaching net zero by 2040, as set out in its Climate Transition Plan published in 2025. This aspiration reflects PMI’s confidence in collective progress, trust that ambition drives innovation, that policy will evolve to enable change, and collaboration will accelerate system‑wide transformation. Above all, it signals hope: that by acting early and h
Mobius Renewables Acquires Air Liquide’s Biogas Production Activities in the United States, France, Norway, and Sweden4.5.2026 08:45:00 CEST | Press release
Mobius Renewables today announced the closing of the acquisition of Air Liquide’s biogas production activities in the United States, France, Norway, and Sweden. The acquisition includes six operating landfill gas-to-RNG (Renewable Natural Gas) sites in the U.S., five operating farm waste sites in France, and a 51% interest in Redo Biosolutions with production and distribution assets across Norway and Sweden. The acquired portfolio will be a meaningful addition to Mobius Renewables (“the Company”), a global, vertically integrated low carbon fuels platform established in December 2025 by funds managed by IFM Investors to accelerate the development, production, distribution, and commercialization of RNG at scale across North America and Europe. The Company is headquartered in Houston, Texas with additional offices in the United States, France, Norway, and Sweden. With this transaction, the establishment of Mobius Renewables is complete, and GreenGasUSA and the acquired portfolio will oper
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom